{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(5)"],"submitter":["Quesada S"],"funding":["GSK"],"pubmed_abstract":["<h4>Background</h4>Interindividual variability in pharmacokinetics may influence clinical outcomes of niraparib in patients with platinum-sensitive recurrent ovarian cancer (ROC). We aimed to investigate the pharmacokinetic-pharmacodynamic (PK-PD) relationship of niraparib in 49 patients with ROC from the multicenter phase IV NiQoLe study.<h4>Materials and methods</h4>Steady-state trough concentrations (C<sub>min,ss</sub>) on days 8 (D8) and 90 (D90) after treatment initiation were analyzed in the PK-PD analysis in regard to early dose-limiting toxicity (DLT) during the first 3 months of treatment, self-reported adverse events [Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)], and progression-free survival (PFS). Logistic regression and Co"],"journal":["ESMO open"],"pagination":["105054"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12018549"],"repository":["biostudies-literature"],"pubmed_title":["Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study."],"pmcid":["PMC12018549"],"pubmed_authors":["Fabbro M","Grellety T","Le Roux D","Fournel P","Jouinot A","Blanchet B","Combe P","Lebreton C","Joly F","Emambux S","Brachet PE","Hardy-Bessard AC","Thomas R","Follana P","Puszkiel A","Quesada S","Kalbacher E","Alexandre J","Selle F","Mille D","Spaeth D"],"additional_accession":[]},"is_claimable":false,"name":"Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study.","description":"<h4>Background</h4>Interindividual variability in pharmacokinetics may influence clinical outcomes of niraparib in patients with platinum-sensitive recurrent ovarian cancer (ROC). We aimed to investigate the pharmacokinetic-pharmacodynamic (PK-PD) relationship of niraparib in 49 patients with ROC from the multicenter phase IV NiQoLe study.<h4>Materials and methods</h4>Steady-state trough concentrations (C<sub>min,ss</sub>) on days 8 (D8) and 90 (D90) after treatment initiation were analyzed in the PK-PD analysis in regard to early dose-limiting toxicity (DLT) during the first 3 months of treatment, self-reported adverse events [Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)], and progression-free survival (PFS). Logistic regression and Co","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-06T03:04:23.485Z","creation":"2025-07-06T03:04:23.485Z"},"accession":"S-EPMC12018549","cross_references":{"pubmed":["40220450"],"doi":["10.1016/j.esmoop.2025.105054"]}}